Financial Performance - Total revenue for the third quarter was CNY 175,049,000, a decrease of 49.6% compared to CNY 347,069,480 in the same period last year[4] - Net profit attributable to shareholders was CNY -13,623,704.84, representing a decline of 158.6% from CNY 5,133,834.9 year-on-year[5] - Basic earnings per share were CNY -0.04, down from CNY 0.01 in the same quarter last year, reflecting a decrease of 400%[5] - Total operating revenue for the first three quarters of 2025 was CNY 682,719,912.56, a decrease of 33.9% compared to CNY 1,032,589,239.77 in the same period of 2024[24] - Net profit for the first three quarters of 2025 was a loss of CNY 7,547,153.80, compared to a loss of CNY 113,303,466.75 in the same period of 2024[25] - The total comprehensive income attributable to the parent company was -11,213,924.18 RMB, compared to -117,548,926.75 RMB in the previous period[26] - The company reported a basic and diluted earnings per share of -0.03 RMB, compared to -0.29 RMB in the previous period[26] Cash Flow and Assets - Operating cash flow for the period was CNY 44,336,879.79, a significant improvement from CNY -53,787,151 in the previous year[5] - The company's cash and cash equivalents decreased to CNY 110,738,401.92 as of September 30, 2025, from CNY 254,293,484.89 at the end of 2024, representing a decline of 56.5%[20] - The net cash flow from operating activities for the first three quarters of 2025 was 58,490,902.46 RMB, a significant improvement from -204,905,985.53 RMB in the same period of 2024[28] - Cash inflow from operating activities totaled 632,257,945.39 RMB, while cash outflow was 573,767,042.93 RMB, resulting in a positive net cash flow[29] - The ending cash and cash equivalents balance was 93,792,931.85 RMB, down from 135,834,728.73 RMB in the previous year[30] - Total assets at the end of the reporting period were CNY 2,799,785,053.43, a decrease of 5.56% from CNY 2,964,546,337.76 at the end of the previous year[5] - Total liabilities decreased to CNY 2,064,133,355.83 as of September 30, 2025, down 7.1% from CNY 2,221,262,004.67 at the end of 2024[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,294[13] - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 167,079,000 shares, accounting for 41.76% of total shares[13] - The second-largest shareholder, Zhejiang Fuwang Juder Health Development Co., Ltd., holds 57,519,000 shares, representing 14.38%[14] Operational Adjustments and Compliance - The company is undergoing adjustments due to prior accounting errors as mandated by regulatory authorities, affecting previously reported financial data[6] - The company has implemented a special rectification team to address issues raised in the internal control audit report, led by the chairman[16] - The company is enhancing its internal control management by conducting comprehensive self-inspections and reinforcing contract risk prevention measures[16] - Financial data review processes have been established to ensure compliance with accounting standards and improve financial data management[17] - The company plans to strengthen communication with regulatory authorities to enhance compliance management and risk prevention capabilities[17] - The company will continue to optimize its governance structure and improve the quality of information disclosure[17] Revenue and Cost Trends - Operating revenue decreased by 33.88% year-on-year due to cyclical market demand adjustments and industry policy impacts[10] - Total operating costs for the first three quarters of 2025 were CNY 697,724,259.32, down 41.2% from CNY 1,186,983,292.11 in the previous year[24] - The company reported a significant reduction in research and development expenses to CNY 20,326,657.01 in the first three quarters of 2025, down 85.1% from CNY 136,399,436.30 in the same period of 2024[25] - The company incurred cash payments for purchasing goods and services totaling 189,063,254.82 RMB, significantly lower than 482,310,778.21 RMB in the same period last year[29] Non-Operating Income - Non-operating income for the period included government subsidies amounting to CNY 13,502,190.71, contributing positively to the financial results[8] - The company reported a total of CNY 13,426,521.53 in non-recurring gains and losses for the year-to-date, indicating a significant impact on overall profitability[9] - The company received tax refunds amounting to 185,533.02 RMB, a decrease from 2,308,531.23 RMB in the previous year[29]

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of "Children's Danqing Shuangjie Granules" aimed at treating pediatric influenza with a specific syndrome [1][4] - The drug is classified as a Category 1.1 innovative traditional Chinese medicine, focusing on clearing heat and detoxifying, and is intended for children with influenza presenting with both exterior and interior heat symptoms [2][3] - Following the approval, the drug must undergo clinical trials and receive further evaluation from the National Medical Products Administration before it can be manufactured and marketed [4] Group 2 - The clinical trial application for "Children's Danqing Shuangjie Granules" was accepted on August 11, 2025, and is in compliance with the relevant drug registration requirements [1][2] - The drug's core efficacy includes clearing heat, relieving fire, and detoxifying, specifically targeting the symptoms associated with pediatric influenza [2] - The company will fulfill its information disclosure obligations based on the progress of the drug development [5]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-080 海南葫芦娃药业集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收 到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于 小儿胆青双解颗粒的《药物临床试验批准通知书》，同意本品开展临 床试验。现将有关情况公告如下： 一、药品基本情况 药物名称：小儿胆青双解颗粒 申请事项：临床试验 受理号：CXZL2500065 本次申请进行临床试验的"小儿胆青双解颗粒"是针对流行性感 冒的病理转归，经多年实践反复验证，总结筛选出表里双解、清热解 毒的有效方剂。核心功效为清热透表，泻火解毒，表里双解。用于儿 童流行性感冒表里俱热证。 按照《中药注册分类及申报资料要求》（2020 年第 68 号），本品 属于中药创新药 1.1 类。 三、产品上市尚需履行的审批程序 根据我国药品注册相关的法律法规要求，药物在取得药物临床试 验批准通知书后，尚需开展临床试验并经 ...

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for clinical trials of its pediatric medicine, Xiaoer Danqing Shuangjie Granules, indicating progress in the development of innovative traditional Chinese medicine for treating children's influenza [1] Company Summary - The company has announced the receipt of a clinical trial approval notice for Xiaoer Danqing Shuangjie Granules, which is classified as a Category 1.1 innovative traditional Chinese medicine [1] - The core efficacy of the drug is to clear heat and relieve toxicity, addressing both exterior and interior symptoms associated with pediatric influenza [1]

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [2] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' kidney function [4] - Kelun Pharmaceutical's subsidiary obtained approval for its targeted antibody-drug conjugate, Boduocizumab, for treating HER2-positive breast cancer patients who have received prior anti-HER2 therapies, showing significant improvement in progression-free survival [5] Financial Reports - Wowo Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenues of 625 million yuan [7] - Pianzaihuang's third-quarter net profit decreased by 28.82% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector and declining gross margins [8] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Purui Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [11] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted antibody-drug conjugate for colorectal cancer [12][13] - Maipu Medical plans to acquire 100% of Guangzhou Yijie Medical Technology for 335 million yuan and raise additional funds [15] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [18]

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the draft Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [1] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' glomerular filtration rate [2] - Kelun Pharmaceutical's subsidiary obtained approval for its ADC product, Botuzumab, for treating HER2-positive breast cancer, showing significant improvement in progression-free survival compared to T-DM1 [3] Financial Reports - WoHua Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenue of 625 million yuan [4] - Pianzihuang's third-quarter net profit decreased by 28.82%, with revenue down 26.28% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector [5] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Puri Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [7] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted ADC for colorectal cancer [8] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [12]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-078 海南葫芦娃药业集团股份有限公司 关于董事会换届完成并聘任高级管理人员及 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 17 日召开 2025 年第二次临时股东大会，会议选举产生了公司 3 名非独立董事和 3 名独立董事，并与 2025 年 10 月 15 日召开的职工代表大会选举产生的 1 名职工 代表董事共同组成公司第五届董事会。在完成董事会换届选举后，公司于同日召 开了第四届董事会 2025 年第一次临时会议，选举产生了董事长、各专门委员会， 并聘任第四届高级管理人员及证券事务代表。现将相关情况公告如下： 一、公司第四届董事会组成情况 1、战略与 ESG 委员会 主任委员：刘景萍 委员：林慧、王清涛 2、审计委员会 主任委员：刘秋云 委员：王世贤、汤琪波 3、提名委员会 以上任期从公司 2025 年第二次临时股东大会审议通过之日起三年。 二、高级管理 ...

海南葫芦娃药业集团股份有限公司 重要内容提示： 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-079 关于拟与关联方签署技术合作开发合同暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 ● 交易简要内容：海南葫芦娃药业集团股份有限公司（以下简称"公司"）拟与 杭州康领先医药科技有限公司（以下简称"康领先"）签署两个项目的《技术合作开发 合同》（以下简称"本项目"或"项目"），共同开发"昂丹司琼口溶膜"、"依达拉 奉右莰醇注射用浓溶液"项目，合同金额预估分别为 910 万元和 215 万元，共计 1,125 万元。 ● 本次交易构成关联交易，未构成重大资产重组。 ● 本次关联交易已经公司第四届董事会 2025 年第一次临时会议审议通过，并已经 独立董事专门会议事先审议通过，无需提交股东大会审议。 （二）关联人基本情况 ● 至本次关联交易为止，过去12个月内公司与同一关联人康领先发生的关联交易 累计0次，累计金额0万元，与不同关联人之间未发生交易类别相关的关联交易。 ● 鉴于药物研发周期较长， ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-076 海南葫芦娃药业集团股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 17 日 (二)股东大会召开的地点：海南省海口市秀英区安读一路 30 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 233 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 303,558,250 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 75.8689 | 1、公司在任董事7人，列席7人，其中独立董事列席 3 人； 2、公司在任监事3人，列席3人； 3、董事会秘书王清涛先生列席本次会议；公司全体高级管理人员列席会议。 二、 议案审议情况 (一)非累 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-077 海南葫芦娃药业集团股份有限公司 第四届董事会 2025 年第一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第四届董事会 2025 年第一次临时会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关规 定，会议合法有效。 （二）会议通知于 2025 年 10 月 17 日以口头方式发出，全体董事同意豁免提前 3 日发出会议通知的期限。 （三）会议于 2025 年 10 月 17 日在海南省海口市秀英区安读一路 30 号公司会议室 以现场方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体高级管理人员列席会议。 二、董事会会议审议情况 （一）审议通过了《关于选举第四届董事会董事长的议案》 同意选举刘景萍女士为公司第四届董事会董事长，任期自本次董事会审议通过之日 起至本届董 ...